LitCovid-sample-Enju  

PMC:7228307 / 60295-61605 JSONTXT 15 Projects

Annnotations TAB TSV DIC JSON TextAE

Id Subject Object Predicate Lexical cue
T455 0-6 JJ denotes Future
T456 7-17 NNS denotes directions
T457 18-20 IN denotes in
T458 21-24 DT denotes the
T459 25-36 NN denotes development
T460 37-40 CC denotes and
T461 41-44 NN denotes use
T462 45-47 IN denotes of
T463 48-59 JJ denotes therapeutic
T464 60-70 NNS denotes antibodies
T465 71-77 MD denotes should
T466 78-90 RB denotes increasingly
T467 91-96 VB denotes mimic
T468 97-103 JJ denotes normal
T469 104-114 JJ denotes protective
T470 115-123 NN denotes antibody
T471 124-133 NNS denotes responses
T472 133-134 -COMMA- denotes ,
T473 135-140 WDT denotes which
T474 141-144 VBP denotes are
T475 145-155 JJ denotes polyclonal
T476 156-159 CC denotes and
T477 160-168 VBN denotes elicited
T478 169-171 IN denotes in
T479 172-175 DT denotes the
T480 176-183 NN denotes context
T481 184-186 IN denotes of
T482 187-193 JJ denotes innate
T483 194-202 NN denotes receptor
T484 203-213 NN denotes engagement
T485 214-219 WDT denotes which
T486 220-228 VBZ denotes includes
T487 229-232 DT denotes the
T488 233-236 NNS denotes FcR
T489 237-239 RB denotes as
T490 240-244 RB denotes well
T491 245-247 IN denotes as
T492 248-253 JJ denotes other
T493 254-264 RB denotes powerfully
T494 265-275 JJ denotes responsive
T495 276-283 NNS denotes systems
T496 284-293 VBG denotes including
T497 294-297 DT denotes the
T498 298-307 JJ denotes Toll‐like
T499 308-317 NNS denotes receptors
T500 318-321 CC denotes and
T501 322-332 NN denotes complement
T502 333-342 NNS denotes receptors
T503 344-355 RB denotes Furthermore
T504 355-356 -COMMA- denotes ,
T505 357-360 DT denotes the
T506 361-366 JJ denotes mixed
T507 367-375 NN denotes subclass
T508 376-382 NN denotes nature
T509 383-385 IN denotes of
T510 386-391 DT denotes these
T511 392-398 JJ denotes normal
T512 399-407 NN denotes antibody
T513 408-417 NNS denotes responses
T514 418-426 VBZ denotes suggests
T515 427-431 IN denotes that
T516 432-445 NNS denotes circumstances
T517 446-449 MD denotes may
T518 450-455 VB denotes arise
T519 456-458 IN denotes in
T520 459-470 JJ denotes therapeutic
T521 471-481 NNS denotes strategies
T522 482-487 WRB denotes where
T523 488-493 EX denotes there
T524 494-496 VBZ denotes is
T525 497-502 NN denotes value
T526 503-505 IN denotes in
T527 506-512 VBG denotes having
T528 513-523 RB denotes distinctly
T529 524-532 VBN denotes modified
T530 533-536 NNS denotes Fcs
T531 537-540 IN denotes for
T532 541-544 DT denotes the
T533 545-552 JJ denotes nuanced
T534 553-563 NN denotes engagement
T535 564-566 IN denotes of
T536 567-576 JJ denotes different
T537 577-581 NN denotes FcγR
T538 582-588 NN denotes family
T539 589-596 NNS denotes members
T540 598-608 NNS denotes Treatments
T541 609-619 VBG denotes comprising
T542 620-628 JJ denotes multiple
T543 629-633 NNS denotes mAbs
T544 634-637 CC denotes and
T545 638-644 JJ denotes immune
T546 645-655 NNS denotes stimulants
T547 656-659 VBP denotes are
T548 660-665 IN denotes under
T549 666-679 NN denotes investigation
T550 680-682 IN denotes in
T551 683-693 JJ denotes infectious
T552 694-701 NN denotes disease
T553 702-705 IN denotes for
T554 706-720 NN denotes neutralization
T555 721-729 NN denotes coverage
T556 730-732 IN denotes of
T557 733-740 JJ denotes variant
T558 741-748 NNS denotes strains
T559 750-756 RB denotes Indeed
T560 756-757 -COMMA- denotes ,
T561 758-762 PDT denotes such
T562 763-765 DT denotes an
T563 766-774 NN denotes approach
T564 775-778 MD denotes may
T565 779-781 VB denotes be
T566 782-786 RBS denotes most
T567 787-796 JJ denotes effective
T568 797-799 IN denotes in
T569 800-808 VBG denotes emerging
T570 809-819 JJ denotes infectious
T571 820-827 NN denotes disease
T572 828-832 JJ denotes such
T573 833-835 IN denotes as
T574 836-842 JJ denotes severe
T575 843-848 JJ denotes acute
T576 849-860 JJ denotes respiratory
T577 861-869 NN denotes syndrome
T578 870-881 NN denotes coronavirus
T579 882-883 CD denotes 2
T580 884-885 -LRB- denotes (
T581 885-895 NN denotes SARS‐CoV‐2
T582 895-896 -RRB- denotes )
T583 897-906 NN denotes infection
T584 908-911 DT denotes The
T585 912-915 NN denotes use
T586 916-918 IN denotes of
T587 919-927 JJ denotes multiple
T588 928-932 NNS denotes mAbs
T589 933-941 VBN denotes tailored
T590 942-945 IN denotes for
T591 946-954 JJ denotes distinct
T592 955-963 NN denotes effector
T593 964-973 NNS denotes functions
T594 974-977 CC denotes and
T595 978-987 VBG denotes targeting
T596 988-997 JJ denotes different
T597 998-1006 NNS denotes epitopes
T598 1007-1011 MD denotes will
T599 1012-1020 VB denotes maximize
T600 1021-1024 DT denotes the
T601 1025-1036 NN denotes opportunity
T602 1037-1040 IN denotes for
T603 1041-1052 NN denotes cocktailing
T604 1053-1055 IN denotes of
T605 1056-1064 NN denotes effector
T606 1065-1074 NNS denotes functions
T607 1075-1077 IN denotes in
T608 1078-1087 JJ denotes different
T609 1088-1093 NNS denotes types
T610 1094-1096 IN denotes of
T611 1097-1105 NNS denotes diseases
T612 1107-1113 RB denotes Indeed
T613 1113-1114 -COMMA- denotes ,
T614 1115-1117 IN denotes in
T615 1118-1119 DT denotes a
T616 1120-1125 JJ denotes small
T617 1126-1129 CC denotes but
T618 1130-1142 JJ denotes contemporary
T619 1143-1150 NN denotes example
T620 1151-1158 IN denotes outside
T621 1159-1161 IN denotes of
T622 1162-1172 JJ denotes infectious
T623 1173-1180 NN denotes disease
T624 1180-1181 -COMMA- denotes ,
T625 1182-1185 DT denotes the
T626 1186-1198 NNP denotes FDA‐approved
T627 1199-1210 NN denotes combination
T628 1211-1213 IN denotes in
T629 1214-1228 NN denotes adenocarcinoma
T630 1229-1236 NN denotes therapy
T631 1237-1241 VBZ denotes uses
T632 1242-1243 DT denotes a
T633 1244-1252 NN denotes cocktail
T634 1253-1255 IN denotes of
T635 1256-1259 CD denotes two
T636 1260-1264 NNS denotes mAbs
T637 1264-1265 -COMMA- denotes ,
T638 1266-1276 NN denotes pertuzumab
T639 1277-1280 CC denotes and
T640 1281-1292 NN denotes trastuzumab
T641 1292-1293 -COMMA- denotes ,
T642 1294-1301 IN denotes against
T643 1302-1310 NN denotes Her2.123
R467 T456 T455 arg1Of directions,Future
R468 T456 T457 arg1Of directions,in
R469 T460 T457 arg2Of and,in
R470 T460 T458 arg1Of and,the
R471 T459 T460 arg1Of development,and
R472 T461 T460 arg2Of use,and
R473 T460 T462 arg1Of and,of
R474 T464 T462 arg2Of antibodies,of
R475 T464 T463 arg1Of antibodies,therapeutic
R476 T456 T465 arg1Of directions,should
R477 T467 T465 arg2Of mimic,should
R478 T467 T466 arg1Of mimic,increasingly
R479 T456 T467 arg1Of directions,mimic
R480 T471 T467 arg2Of responses,mimic
R481 T471 T468 arg1Of responses,normal
R482 T471 T469 arg1Of responses,protective
R483 T471 T470 arg1Of responses,antibody
R484 T471 T472 arg1Of responses,","
R485 T471 T473 arg1Of responses,which
R486 T471 T474 arg1Of responses,are
R487 T476 T474 arg2Of and,are
R488 T471 T475 arg1Of responses,polyclonal
R489 T475 T476 arg1Of polyclonal,and
R490 T477 T476 arg2Of elicited,and
R491 T471 T477 arg2Of responses,elicited
R492 T477 T478 arg1Of elicited,in
R493 T480 T478 arg2Of context,in
R494 T480 T479 arg1Of context,the
R495 T480 T481 arg1Of context,of
R496 T484 T481 arg2Of engagement,of
R497 T484 T482 arg1Of engagement,innate
R498 T484 T483 arg1Of engagement,receptor
R499 T480 T485 arg1Of context,which
R500 T480 T486 arg1Of context,includes
R501 T491 T486 arg2Of as,includes
R502 T491 T487 arg1Of as,the
R503 T491 T489 arg1Of as,as
R504 T491 T490 arg1Of as,well
R505 T488 T491 arg1Of FcR,as
R506 T495 T491 arg2Of systems,as
R507 T495 T492 arg1Of systems,other
R508 T495 T493 arg1Of systems,powerfully
R509 T495 T494 arg1Of systems,responsive
R510 T495 T496 arg1Of systems,including
R511 T500 T496 arg2Of and,including
R512 T500 T497 arg1Of and,the
R513 T499 T498 arg1Of receptors,Toll‐like
R514 T499 T500 arg1Of receptors,and
R515 T502 T500 arg2Of receptors,and
R516 T502 T501 arg1Of receptors,complement
R517 T514 T503 arg1Of suggests,Furthermore
R518 T514 T504 arg1Of suggests,","
R519 T508 T505 arg1Of nature,the
R520 T508 T506 arg1Of nature,mixed
R521 T508 T507 arg1Of nature,subclass
R522 T508 T509 arg1Of nature,of
R523 T513 T509 arg2Of responses,of
R524 T513 T510 arg1Of responses,these
R525 T513 T511 arg1Of responses,normal
R526 T513 T512 arg1Of responses,antibody
R527 T508 T514 arg1Of nature,suggests
R528 T518 T514 arg2Of arise,suggests
R529 T518 T515 arg1Of arise,that
R530 T516 T517 arg1Of circumstances,may
R531 T518 T517 arg2Of arise,may
R532 T516 T518 arg1Of circumstances,arise
R533 T518 T519 arg1Of arise,in
R534 T521 T519 arg2Of strategies,in
R535 T521 T520 arg1Of strategies,therapeutic
R536 T521 T522 arg1Of strategies,where
R537 T524 T522 arg2Of is,where
R538 T523 T524 arg1Of there,is
R539 T525 T524 arg2Of value,is
R540 T525 T526 arg1Of value,in
R541 T527 T526 arg2Of having,in
R542 T530 T527 arg2Of Fcs,having
R543 T530 T528 arg1Of Fcs,distinctly
R544 T530 T529 arg2Of Fcs,modified
R545 T530 T531 arg1Of Fcs,for
R546 T534 T531 arg2Of engagement,for
R547 T534 T532 arg1Of engagement,the
R548 T534 T533 arg1Of engagement,nuanced
R549 T534 T535 arg1Of engagement,of
R550 T539 T535 arg2Of members,of
R551 T539 T536 arg1Of members,different
R552 T539 T537 arg1Of members,FcγR
R553 T539 T538 arg1Of members,family
R554 T540 T541 arg1Of Treatments,comprising
R555 T544 T541 arg2Of and,comprising
R556 T543 T542 arg1Of mAbs,multiple
R557 T543 T544 arg1Of mAbs,and
R558 T546 T544 arg2Of stimulants,and
R559 T546 T545 arg1Of stimulants,immune
R560 T540 T547 arg1Of Treatments,are
R561 T548 T547 arg2Of under,are
R562 T540 T548 arg1Of Treatments,under
R563 T549 T548 arg2Of investigation,under
R564 T547 T550 arg1Of are,in
R565 T552 T550 arg2Of disease,in
R566 T552 T551 arg1Of disease,infectious
R567 T552 T553 arg1Of disease,for
R568 T555 T553 arg2Of coverage,for
R569 T555 T554 arg1Of coverage,neutralization
R570 T555 T556 arg1Of coverage,of
R571 T558 T556 arg2Of strains,of
R572 T558 T557 arg1Of strains,variant
R573 T565 T559 arg1Of be,Indeed
R574 T565 T560 arg1Of be,","
R575 T563 T561 arg1Of approach,such
R576 T563 T562 arg1Of approach,an
R577 T563 T564 arg1Of approach,may
R578 T565 T564 arg2Of be,may
R579 T563 T565 arg1Of approach,be
R580 T567 T565 arg2Of effective,be
R581 T567 T566 arg1Of effective,most
R582 T563 T567 arg1Of approach,effective
R583 T567 T568 arg1Of effective,in
R584 T569 T568 arg2Of emerging,in
R585 T571 T569 arg2Of disease,emerging
R586 T571 T570 arg1Of disease,infectious
R587 T573 T572 arg1Of as,such
R588 T571 T573 arg1Of disease,as
R589 T583 T573 arg2Of infection,as
R590 T576 T574 arg1Of respiratory,severe
R591 T576 T575 arg1Of respiratory,acute
R592 T583 T576 arg1Of infection,respiratory
R593 T583 T577 arg1Of infection,syndrome
R594 T583 T578 arg1Of infection,coronavirus
R595 T583 T579 arg1Of infection,2
R596 T583 T580 arg1Of infection,(
R597 T581 T580 arg2Of SARS‐CoV‐2,(
R598 T582 T580 arg3Of ),(
R599 T585 T584 arg1Of use,The
R600 T585 T586 arg1Of use,of
R601 T588 T586 arg2Of mAbs,of
R602 T588 T587 arg1Of mAbs,multiple
R603 T588 T589 arg2Of mAbs,tailored
R604 T589 T590 arg1Of tailored,for
R605 T593 T590 arg2Of functions,for
R606 T593 T591 arg1Of functions,distinct
R607 T593 T592 arg1Of functions,effector
R608 T589 T594 arg1Of tailored,and
R609 T595 T594 arg2Of targeting,and
R610 T588 T595 arg1Of mAbs,targeting
R611 T597 T595 arg2Of epitopes,targeting
R612 T597 T596 arg1Of epitopes,different
R613 T585 T598 arg1Of use,will
R614 T599 T598 arg2Of maximize,will
R615 T585 T599 arg1Of use,maximize
R616 T601 T599 arg2Of opportunity,maximize
R617 T601 T600 arg1Of opportunity,the
R618 T601 T602 arg1Of opportunity,for
R619 T603 T602 arg2Of cocktailing,for
R620 T603 T604 arg1Of cocktailing,of
R621 T606 T604 arg2Of functions,of
R622 T606 T605 arg1Of functions,effector
R623 T599 T607 arg1Of maximize,in
R624 T609 T607 arg2Of types,in
R625 T609 T608 arg1Of types,different
R626 T609 T610 arg1Of types,of
R627 T611 T610 arg2Of diseases,of
R628 T631 T612 arg1Of uses,Indeed
R629 T631 T613 arg1Of uses,","
R630 T631 T614 arg1Of uses,in
R631 T619 T614 arg2Of example,in
R632 T619 T615 arg1Of example,a
R633 T619 T616 arg1Of example,small
R634 T616 T617 arg1Of small,but
R635 T618 T617 arg2Of contemporary,but
R636 T619 T618 arg1Of example,contemporary
R637 T619 T620 arg1Of example,outside
R638 T620 T621 arg1Of outside,of
R639 T623 T621 arg2Of disease,of
R640 T623 T622 arg1Of disease,infectious
R641 T631 T624 arg1Of uses,","
R642 T627 T625 arg1Of combination,the
R643 T627 T626 arg1Of combination,FDA‐approved
R644 T627 T628 arg1Of combination,in
R645 T630 T628 arg2Of therapy,in
R646 T630 T629 arg1Of therapy,adenocarcinoma
R647 T627 T631 arg1Of combination,uses
R648 T633 T631 arg2Of cocktail,uses
R649 T633 T632 arg1Of cocktail,a
R650 T633 T634 arg1Of cocktail,of
R651 T636 T634 arg2Of mAbs,of
R652 T636 T635 arg1Of mAbs,two
R653 T633 T637 arg1Of cocktail,","
R654 T639 T637 arg2Of and,","
R655 T638 T639 arg1Of pertuzumab,and
R656 T640 T639 arg2Of trastuzumab,and
R657 T631 T641 arg1Of uses,","
R658 T631 T642 arg1Of uses,against
R659 T643 T642 arg2Of Her2.123,against